KRRO Korro Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1703647 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-82.5%
TTM net income YoY-20.0%
TTM EPS YoY5.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,467.3%
Net margin-8,214.5%
FCF margin-4,943.8%
EBITDA margin-8,325.8%
Returns
ROE-113.3%
ROA-68.5%
ROIC (approx.)-140.5%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets40.3%
Debt / equity0.00x
Current ratio7.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-27.4%
Payout ratio—
Capex / revenue13.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $1.29M | $1.09M | $1.46M | $2.55M | $2.27M |
| R&D expense | $12.10M | $13.59M | $12.95M | $10.98M | $13.82M | $20.14M | $19.74M | $16.96M |
| SG&A expense | $6.35M | $6.52M | $7.49M | $6.19M | $6.51M | $7.29M | $7.83M | $8.35M |
| Operating income | -$18.46M | -$20.11M | -$20.44M | -$50.40M | -$19.24M | -$27.20M | -$25.02M | -$23.04M |
| Pretax income | -$17.29M | -$18.81M | -$19.53M | -$49.41M | -$18.06M | -$25.77M | -$23.39M | -$21.10M |
| Income tax | $260,000 | $108,000 | $95,000 | $636,000 | $0 | $1,000 | $0 | $103,000 |
| Net income | -$17.55M | -$18.92M | -$19.62M | -$50.04M | -$18.06M | -$25.77M | -$23.39M | -$21.20M |
| EBITDA | -$18.06M | -$19.71M | -$20.06M | -$49.75M | -$18.04M | -$26.00M | -$23.80M | -$21.79M |
| EPS (basic) | -0.98 | -1.07 | -1.69 | — | -1.92 | -2.74 | -2.49 | — |
| EPS (diluted) | -0.98 | -1.07 | -1.69 | — | -1.92 | -2.74 | -2.49 | — |
| Weighted avg. shares (diluted) | 17.87M | 17.62M | 11.60M | — | 9.39M | 9.39M | 9.38M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $40.22M | $24.91M | $61.70M | $21.82M | $24.16M | $33.61M | $64.14M | $55.64M |
| Short-term investments | $64.78M | $90.13M | $52.27M | $53.33M | $68.32M | $62.75M | $50.81M | $70.45M |
| Current assets | $108.94M | $120.63M | $120.16M | $82.37M | $98.23M | $102.63M | $121.23M | $131.53M |
| PP&E, net | $7.24M | $7.48M | $7.80M | $8.16M | $24.40M | $25.39M | $26.68M | $27.71M |
| Total assets | $148.12M | $163.45M | $183.62M | $113.51M | $161.55M | $180.43M | $202.21M | $226.24M |
| Current liabilities | $14.92M | $12.63M | $14.79M | $11.94M | $14.64M | $17.17M | $12.88M | $14.96M |
| Total liabilities | $59.75M | $60.22M | $63.99M | $62.07M | $62.52M | $65.32M | $63.25M | $65.83M |
| Shareholders' equity | $88.37M | $103.23M | $119.63M | $51.44M | $99.03M | $115.10M | $138.96M | $160.41M |
| Shares outstanding | 13.73M | 14.71M | 14.42M | 9.42M | 9.40M | 9.39M | 9.39M | 9.38M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.94M | -$16.99M | -$16.07M | -$17.70M | -$17.18M | -$19.23M | -$24.45M | -$7.50M |
| Capital expenditure | $27,000 | $37,000 | $21,000 | $84,000 | $175,000 | $140,000 | $119,000 | $1.45M |
| Free cash flow | -$12.96M | -$17.03M | -$16.09M | -$17.79M | -$17.35M | -$19.37M | -$24.57M | -$8.95M |
| Investing cash flow | $28.26M | -$17.90M | -$32.24M | $14.92M | $7.60M | -$11.30M | $32.78M | -$2.77M |
| Financing cash flow | $0 | -$2.92M | $88.21M | $380,000 | $128,000 | $5,000 | $172,000 | $932,000 |
| Depreciation & amortization | $400,000 | $400,000 | $380,000 | $649,000 | $1.20M | $1.20M | $1.23M | $1.25M |
| Stock-based compensation | $2.81M | $2.70M | $2.73M | $2.07M | $1.82M | $2.00M | $1.76M | $1.36M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.